Inapparent Von Willebrand Disease as the Underlying Cause of Menorrhagia Attributed to Uterine Fibroids.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4084-4084
Author(s):  
Tarek Mohamed ◽  
Tatyana Sycheva ◽  
Douglas R. Schneider ◽  
Swati R. Chokalingam ◽  
Robert Weinstein

Abstract Menorrhagia is a public health issue affecting 15% of American women, 300,000 of whom undergo hysterectomy each year. 50% of menorrhagia cases are not explained by gynecological disorders like uterine fibroids but in up to 1/3 of such cases bleeding disorders such as von Willebrand disease (vWd) may be present. No cases have been reported to indicate whether women with fibroids and menorrhagia should be investigated for vWd, particularly when screening tests (aPTT or bleeding time) are normal. We report herein 2 cases which demonstrate that inapparent vWd (normal screening tests) should indeed be sought in certain such cases of menorrhagia. Patient #1 was a 44 y/o African-American woman with severe menorrhagia since menarche, multiple 2 cm fibroids and severe iron deficiency anemia (Hgb 7.9 g/dl; MCV 68.5 FL; ferritin 1 ng/ml). Menstrual periods lasted 7 days. She bled through her clothes the first 1–3 days. Intolerant of oral iron, she required weekly injections of iron sucrose (100 mg) to keep up with menstrual losses. A sister in another state was also known to have menorrhagia. Patient #2 was a 40 year old Caucasian woman with severe menorrhagia since menarche (age 11 years), intramural fibroids and severe iron deficiency anemia (Hb 8.9 g/dl, MCV 64.9 FL, ferritin 4 ng/ml). Menstrual periods lasted 7 days, changing pad every hour for the first 2 days.. She bled through her clothes the first 2–3 days and was unable to keep up with menstrual losses using oral iron. Her younger sister also had menorrhagia. Patient Screening Tests Timing fVIII(%) * vWf Ag (%) * Ristocetin co-factor (%) * vW multimer pattern Comment * reference range: 55–200 #1 PTT 31 sec, BT 6 min, Blood Group O+ Mid cycle 61 54 42 Unknown Normal multimer pattern obtained 30 minutes after pre-op injection of DDAVP and also 4 months post hysterectomy Menses 37 48 23 Type II post hysterectomy 53 52 50 Normal #2 PTT 31.5 sec, BT normal, Blood Group O+ Mid cycle 177 117 120 Normal DDAVP nasal spray shortened menstrual period from 7 days (72 pads) to 5 days(20 pads). Younger sister and nephew subsequently diagnosed with vWd. Menses 74 46 52 Type I These cases illustrate that the assumption that severe menorrhagia is explained by simple anatomical abnormalities such as uterine fibroids may cause a significant hemostatic defect to be overlooked. Even normal screening tests, or vW tests obtained during follicular phase, do not rule out vWd in women with severe menorrhagia. The vW panel should be repeated at the start of menses. Patient #1 demonstrates a hitherto unknown association between uterine fibroids and acquired vWd which was apparently cured by hysterectomy and may suggest a mechanism by which fibroids cause menorrhagia. DDAVP controlled the menorrhagia of Patient #2 and may have done so in Patient #1 as well. Physicians should be alert to the possibility of inapparent vWd as the underlying cause of menorrhagia in women with uterine fibroids. High index of suspicion and careful diagnostic work up may provide an opportunity to avoid needless hysterectomy in some patients.

1993 ◽  
Vol 33 (6) ◽  
pp. 661-661
Author(s):  
Helena U Suzuki ◽  
Mauro B Morais ◽  
Jose N Corral ◽  
Ulisses Fagundes-Neto ◽  
Nelson L Machado

PEDIATRICS ◽  
1963 ◽  
Vol 31 (6) ◽  
pp. 1041-1044
Author(s):  
LOUIS K DIAMOND ◽  
J. LAWRENCE NAIMAN ◽  
DONALD M. ALLEN ◽  
FRANK A. OSKI,

Experience with a new oral iron-carbohydrate complex (Jefron) in the treatment of iron-deficiency anemia shows that the therapeutic results are inferior to those obtainable with ferrous sulfate. Many children showed no response after months of treatment with this drug and when subsequently placed on ferrous sulfate therapy showed a rapid rise in hemoglobin to normal levels. Preliminary studies suggest that poor gastrointestinal absorption may be a factor in the inadequate therapeutic effects.


Author(s):  
Adam K. Lewkowitz ◽  
Molly J. Stout ◽  
Emily Cooke ◽  
Seon C. Deoni ◽  
Viren D'Sa ◽  
...  

Objective Iron-deficiency anemia (IDA) can have serious consequences for mothers and babies. Iron supplementation is recommended, but the administration route is controversial. We sought to conduct a randomized controlled trial (RCT) testing the effectiveness and safety of intravenous (IV) iron compared with oral iron on perinatal outcomes in pregnant women with IDA. Study Design This open-label RCT randomized patients with IDA (hemoglobin [hgb] <10 g/dL and ferritin <30 ng/mL) at 24 to 34 weeks' to oral iron or single 1,000-mg dose of IV low-molecular weight iron dextran over one hour. The primary outcome was maternal anemia at delivery (hgb < 11 g/dL). Secondary outcomes were mild/moderate or severe adverse reactions, maternal hgb and ferritin at delivery, blood transfusion, gestational age at delivery, birth weight, neonatal hgb and ferritin, and composite neonatal morbidity. Analysis was as per protocol. Results The trial was stopped early for logistical reasons, and the data analyzed as preliminary data to inform a larger, potentially externally funded, definitive trial. Of 55 patients approached, 38 consented. Of these, 15 were withdrawn: 5 received IV iron from their primary obstetrician after being randomized to oral iron and 10 declined to receive IV iron. Of the remaining 23 patients, who were included in the analytic population, 13 received oral iron and 10 received IV iron. The rate of maternal anemia at delivery (hgb < 11 g/dL) was high overall but significantly reduced with IV iron (40 vs. 85%, p = 0.039). Rates of maternal hgb < 10 g/dL were significantly lower in the IV iron group (10 vs. 54%, p = 0.029). There were no severe adverse reactions and similar rates of mild/moderate reactions between groups. Conclusion IV iron reduces rates of anemia at the time of admission for delivery, supporting a larger RCT comparing IV versus oral iron for the treatment of IDA of pregnancy powered for definitive clinical outcomes. However, issues uncovered in this RCT suggest that patient, clinician, and systems-level barriers associated with different IDA treatment modalities must be considered prior to conducting a larger RCT. This study is registered with clinicaltrials.gov with identifier no.: NCT03438227. Key Points


Author(s):  
Manal Mahmoud Atia ◽  
Rasha Mohamed Gama ◽  
Mohamed Attia Saad ◽  
Mohammed Amr Hamam

Greater prevalence of iron deficiency (ID) has been observed in overweight and obese children and adolescents. Hepcidin acts as a key regulator of iron metabolism. Hepcidin synthesis increases in response inflammatory cytokines especially Interleukin-6 (IL-6). Considering that obesity represents a low grade chronic inflammatory state, a high concentration of hepcidin has been found in obese children. Elevated hepcidin level in obese children is associated with diminished response to oral iron therapy. Lactoferrin is an iron-binding multifunctional glycoprotein and has strong capacity to modulate the inflammatory response by its capacity to reduce pro-inflammatory cytokine expression in vivo, including IL-6 and hepcidin. Aim of the Work: To compare the efficacy of lactoferrin versus oral iron therapy in treatment of obese children and adolescents with iron deficiency anemia and the effect of therapy on serum hepcidin and interleukin 6 levels. Methodology: This prospective randomized clinical trial was conducted on 40 obese children and adolescents aged between 6 –18 years suffering from iron deficiency anemia (IDA). They were equally randomized into one of 2 groups. Group A received regular oral lactoferrin in a dose of 100 mg/day. Group B received regular oral iron supplementation (Ferric hydroxide polymaltose) in a dose of 6 mg elemental iron/kg /day.Baseline investigations included complete blood count (CBC), iron profile (Serum ferritin, serum iron, total iron binding capacity (TIBC), transferrin saturation), serum Interleukin 6, and serum hepcidin. Reevaluation of CBC was done monthly while iron status parameters, serum IL-6 and serum hepcidin were reevaluated after 3 months of receiving regular therapy. Results: Significant elevations in hemoglobin, MCV, MCH, Serum ferritin, serum iron and transferrin saturation with lactoferrin therapy compared to oral iron therapy. Significantly Lower TIBC after 3 months of lactoferrin therapy while the decrease in TIBC was insignificant in the iron therapy group.Lower serum hepcidin and IL6 after 3 months of lactoferrin therapy with no significant change in serum hepcidin and IL6 after iron therapy. Conclusion: This study clearly demonstrated the superiority of lactoferrin over iron use as oral in the treatment of iron deficiency anemia in obese children not only for the better response of hematological and iron status parameters and less gastrointestinal side effects but also for its effect on decreasing inflammatory biomarkers as hepcidin and IL6.


Sign in / Sign up

Export Citation Format

Share Document